Merck, which previously predicted 2024 sales between 20.7 billion ... continues to regain ground from a slump after the end ...

After-tax profit was 812 million euros compared with 740 million in the same period last year, Merck said Thursday. The ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck was founded in 1668 and is the world’s oldest operating chemical and pharmaceutical company. Asuka Koda covers the Yale ...

Merck, which previously predicted 2024 sales of between 20. ... valuable Life Sciences service that brings together a daily ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...